Terrence Swade, MD
Endocrinology, Diabetes & Metabolism · Lombard, ILNPI 1699847202
Payments from drug & device makers
Across 1,949 payments — averaging $189.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$204K
- Lilly USA, LLC$86K
- Xeris Pharmaceuticals, Inc.$42K
- AstraZeneca$11K
- Sanofi-aventis U.S. LLC$3K
- Tandem Diabetes Care, Inc.$3K
- plus $20K from 54 others
What the payments were for
- Consulting fees$22,9256%
- Speaking & faculty fees$289,65479%
- Travel & lodging$12,9894%
- Food & beverage$42,07211%
- Education$1,0960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$97,808
- MOUNJARO$78,245
- RYBELSUS$61,238
- GVOKE HYPOPEN$39,439
- Tresiba$22,722
- FARXIGA$9,537
- t:slim X2 Insulin Pump with Control-IQ$2,221
- Kerendia$583
- Vascepa$362
- DEXCOM G6 TRANSMITTER$283
- JARDIANCE$250
- SOLIQUA 100/33$224
- MYCAPSSA$150
- Wegovy$130
- DEXCOM G7 GSS (161)$125
- Saxenda$125
- ZEPBOUND$124
- PRALUENT$124
- Pogo Automatic Blood Glucose Monitoring System$124
- t-slim insulin pump$116
How this compares
$368,736 in reported general payments places this provider in the 95th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 379 | $641,949 |
| JardianceEmpagliflozin | 143 | $187,689 |
| MounjaroTirzepatide | 138 | $171,768 |
| JanuviaSitagliptin Phosphate | 84 | $96,024 |
| Tresiba Flextouch U-200Insulin Degludec | 66 | $82,377 |
| FarxigaDapagliflozin Propanediol | 77 | $76,779 |
| Tresiba Flextouch U-100Insulin Degludec | 85 | $66,664 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 48 | $61,629 |
| Humalog Kwikpen U-200Insulin Lispro | 35 | $55,832 |
| RybelsusSemaglutide | 30 | $49,995 |
| TrulicityDulaglutide | 26 | $44,427 |
| KerendiaFinerenone | 32 | $43,496 |
| V-Go 40Sub-Q Insulin Device, 40 Unit | 30 | $30,101 |
| Novolog FlexpenInsulin Aspart | 85 | $27,282 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 48 | $23,968 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $204,250 | $711,245466 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $85,645 | $249,080240 claims |
| Boehringer IngelheimJardiance | $1,547 | $187,689143 claims |
| MerckJanuvia, Janumet | $484 | $108,315103 claims |
| AstraZenecaFarxiga | $11,132 | $76,77977 claims |
| BayerKerendia | $1,741 | $43,49632 claims |
| AbbVieSynthroid | $750 | $17,486159 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $325 | $6,447489 claims |
| PfizerEliquis | $22 | $6,27011 claims |
| Sanofi-aventis U.S. LLCLantus | $3,427 | $4,80730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Lombard
- Jacek ZajacLombard$26K
- Liana BillingsSkokie$3.4M
- Leon FogelfeldChicago$1.5M
- Grazia AleppoChicago$1.4M
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Hiralal MaheshwariMcHenry$642K
- Wenyu HuangChicago$639K
- Babak PazookiJoliet$582K
- Silvana PannainChicago$575K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.